Third Tysabri adverse case hits drug class.
Sheridan
Cormac
C
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000145:classification; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced* / Q000276:immunology; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology; D000069442:Natalizumab; D009422:Nervous System Diseases / Q000139:chemically induced / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab